NCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
13 trialsNCT07510815 2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07502287 2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2 Recruiting
NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04697576 2026-03-10
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT03501576 2026-02-11
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Emory University
Recruiting
NCT05170399 2026-02-05
Vaccine Responses in Patients With B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 4 Recruiting
NCT06605625 2025-10-28
VRiC
Abramson Cancer Center at Penn Medicine
Active not recruiting
NCT03016806 2025-10-10
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
Recruiting
NCT06664151 2025-10-02
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT07052422 2025-07-04
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT03955991 2025-06-26
VSMART
University of Miami
Phase 4 Completed
NCT06124131 2025-05-04
BENEFIT-C
Tulane University
Phase NA Completed